Evidence map›Paper›PMID 33207627›Full record

ArticleCancers2020

Risk Factors for Recurrence after Robot-Assisted Radical Hysterectomy for Early-Stage Cervical Cancer: A Multicenter Retrospective Study.

Jordi Ponce, Sergi Fernandez-Gonzalez, Antonio Gil-Moreno, Pluvio J Coronado, Jesús De la Rosa, Henrique Nabais, Ginés Hernández, Anna Taltavull, Juan Gilabert-Estelles, Sergio Martínez-Román and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

Jordi PonceDepartment of Gynecology, University Hospital of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-0613-2261
Sergi Fernandez-GonzalezDepartment of Gynecology, University Hospital of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-9138-6978
Antonio Gil-MorenoDepartment of Gynecologic Oncology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0003-1106-5590
Pluvio J CoronadoInstituto de Salud de la Mujer, Hospital Clínico San Carlos, Madrid, IdISSC, Universidad Complutense, 28040 Madrid, Spain.
Jesús De la RosaDepartment of Gynecology, Hospital Universitario de Basurto, 48013 Bilbao, Spain.
Henrique NabaisDepartment of Gynecology, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Ginés HernándezDepartment of Gynecology, Hospital Universitario Quirónsalud, 28223 Madrid, Spain.ORCID 0000-0001-9162-3649
Anna TaltavullDepartment of Gynecology, Hospital Universitari Josep Trueta, 17007 Girona, Spain.
Juan Gilabert-EstellesDepartment of Gynecology, Hospital General Universitario de Valencia, University of Valencia, 46014 Valencia, Spain.ORCID 0000-0002-3992-1929
Sergio Martínez-RománDepartment of Gynecology, Hospital Universitari Germans Trias i Pujol, Badalona, 08916 Barcelona, Spain.
Manel BarahonaDepartment of Gynecology, University Hospital of Puerto Real, 11510 Cádiz, Spain.
Marc BarahonaDepartment of Gynecology, University Hospital of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
María Ángeles Martínez-MaestreDepartment of Gynecology, Hospital Universitario Virgen del Rocio, 41013 Sevilla, Spain.
Bellvitge University Hospital · ESChampalimaud Foundation · PTHospital Clínico San Carlos · ESHospital de Basurto · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitario Quirónsalud Madrid · ESHospital Universitario Virgen del Rocío · ESUniversitat de València · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective analysis aimed to assess the risk factors for recurrence in patients diagnosed with early-stage cervical cancer (≤IB1 or IIA1, FIGO 2009) undergoing robot-assisted radical hysterectomy in Spain and Portugal between 2009 and 2018. A second primary objective was to audit the oncological outcomes according to quality indicators (QI) proposed by the European Society of Gynecology Oncology (ESGO). The study population included 239 women. After a median follow-up of 51 months, recurrence occurred in 26 patients (10.9%). Independent factors for recurrence were clinical tumor size > 20 mm (hazard ratio (HR) 2.37), adenocarcinoma as histological type (HR 2.51), positive pelvic lymph nodes (HR 4.83), tumor grade 2 (HR 4.99), tumor grade 3 (HR 8.06), and having not performed sentinel lymph node biopsy (SLNB) (HR 4.08). All 5 QI selected were surpassed by our results. In patients with early-stage cervical cancer undergoing robotic radical hysterectomy, clinicians should be aware that tumor grade 2 and 3, tumor size > 20 mm, adenocarcinoma, positive pelvic nodes, and lack of performance of SLNB are risk factors for recurrence. Fulfillment of QI targets of the ESGO might be considered as an objective oncological outcome indicator supporting the minimally invasive approach for early-stage cervical cancer treatment.

Indexed as

early-stage cervical canceroncological outcomeradical hysterectomyrecurrencerobotic surgery

Identifiers

PMID33207627
PMCPMC7696424
OpenAlexW3100496745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.